Sugi Predict

Sugi Predict / Compounds / SCHEMBL4400997

SCHEMBL4400997

SCHEMBL4400997

O=C(CCc1ccc([N+](=O)[O-])cc1)N1CCC1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNJ1 P48048 5/20 0.51
▸ KCNH2 Q12809 4/20 0.51
▸ MAPT P10636 4/20 0.51
▸ SMN1; SMN2 Q16637 4/20 0.51
▸ ALDH1A1 P00352 4/20 0.51
▸ L3MBTL1 Q9Y468 2/20 0.51
▸ HRH3 Q9Y5N1 1/20 0.49
▸ TSHR P16473 1/20 0.49
▸ NPSR1 Q6W5P4 3/20 0.45
▸ LMNA P02545 2/20 0.45
▸ HPGD P15428 2/20 0.45
▸ HTT P42858 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ POLB P06746 1/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ CYP2C19 P33261 1/20 0.45
▸ RECQL P46063 1/20 0.45
▸ HDAC3 O15379 1/20 0.45
▸ HDAC4 P56524 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16425199 0.87 MAPT (0.60) KCNJ1KCNH2MAPTSMN1; SMN2ALDH1A1
SCHEMBL15073074 0.86 KCNJ1 (0.49) KCNJ1KCNH2MAPTSMN1; SMN2ALDH1A1
SCHEMBL12735068 0.81 NAAA (0.52) MAPTSMN1; SMN2ALDH1A1L3MBTL1LMNA
SCHEMBL2722040 0.81 LMNA (0.46) MAPTSMN1; SMN2TSHRLMNAMAPK1
SCHEMBL4404820 0.80 NPC1 (0.58) MAPTSMN1; SMN2L3MBTL1TSHRLMNA
SCHEMBL15075031 0.79 KMT2A (0.46) MAPTSMN1; SMN2ALDH1A1L3MBTL1LMNA
SCHEMBL30484396 0.78 ALDH1A1 (0.68) KCNJ1KCNH2MAPTSMN1; SMN2ALDH1A1
SCHEMBL4404789 0.78 ALDH1A1 (0.65) KCNJ1KCNH2MAPTSMN1; SMN2ALDH1A1
SCHEMBL20196333 0.77 POLB (0.45) MAPTSMN1; SMN2ALDH1A1TSHRLMNA
SCHEMBL14297019 0.75 POLB (0.49) MAPTSMN1; SMN2ALDH1A1TSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637520-B2 Conjugation chemistry for catalytic antibody 38C2 UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) 2026-05-26 — — US disclosed
US-20230012213-A1 NOVEL CONJUGATION CHEMISTRY FOR CATALYTIC ANTIBODY 38C2 THE SCRIPPS RESEARCH INSTITUTE 2023-01-12 — — US disclosed
EP-4048311-A1 NOVEL CONJUGATION CHEMISTRY FOR CATALYTIC ANTIBODY 38C2 University of Florida Research Foundation, Incorporated (US) 2022-08-31 — — EP disclosed
CN-114846030-A Novel conjugation chemistry that catalyzes antibody 38C2 佛罗里达大学研究基金会公司 2022-08-02 — — CN disclosed
WO-2021080846-A1 NOVEL CONJUGATION CHEMISTRY FOR CATALYTIC ANTTIBODY 38C2 THE SCRIPPS RESEARCH INSTITUTE (US) 2021-04-29 — — WO disclosed
EP-2793928-B1 PROCESS FOR PURIFYING A SAMPLE OF H38C2 ANTIBODY PFIZER (US) 2017-03-15 — — EP disclosed
US-9352050-B2 Processes for preparing peptide conjugates and linkers PFIZER INC. (US) 2016-05-31 — — US disclosed
US-9352050-B2 Processes for preparing peptide conjugates and linkers PFIZER INC. (US) 2016-05-31 — — US disclosed
US-9163227-B2 Anti-diabetic compounds COVX TECHNOLOGIES IRELAND LIMITED (IE) 2015-10-20 — — US disclosed
US-9163227-B2 Anti-diabetic compounds COVX TECHNOLOGIES IRELAND LIMITED (IE) 2015-10-20 — — US disclosed
WO-2012059873-A2 ANTI-DIABETIC COMPOUNDS COVX TECHNOLOGIES IRELAND, LTD. (IE) 2012-05-10 — — WO disclosed
EP-2368908-A2 Anti- angiogenic compounds CovX Technologies Ireland Limited (IE) 2011-09-28 — — EP disclosed
EP-2089425-B1 ANTI-ANGIOGENIC COMPOUNDS COVX TECHNOLOGIES IRELAND LTD (IE) 2011-08-17 — — EP disclosed
US-20110087010-A1 ANTI-ANGIOGENIC COMPOUNDS COVX TECHNOLOGIES IRELAND LIMITED 2011-04-14 — — US disclosed
US-20110087010-A1 ANTI-ANGIOGENIC COMPOUNDS COVX TECHNOLOGIES IRELAND LIMITED 2011-04-14 — — US disclosed
EP-2292248-A2 Anti-angiogenic compounds CovX Technologies Ireland Limited (IE) 2011-03-09 — — EP disclosed
US-7521425-B2 Anti-angiogenic compounds COVX TECHNOLOGIES IRELAND LIMITED (IE) 2009-04-21 — — US disclosed
US-20090098130-A1 GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONIST COMPOUNDS COVX TECHNOLOGIES IRELAND LIMITED (IE) 2009-04-16 — — US disclosed
US-20080166364-A1 Conjugated to antibody; thrombospondin receptor targeting COVX TECHNOLOGY IRELAND, LTD. (IE) 2008-07-10 — — US disclosed
US-20080152660-A1 Anti-Angiogenic Compounds COVX TECHNOLOGIES IRELAND LIMITED (IE) 2008-06-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110087010-A1 ANTI-ANGIOGENIC COMPOUNDS VEGFA, FLT4, KDR KCNJ1 4873/4885KCNH2 4859/4885MAPT 3908/4885
US-12637520-B2 Conjugation chemistry for catalytic antibody 38C2 IGLV6-57, SETD1A, KDM4C KCNJ1 3443/4885KCNH2 2165/4885MAPT 1886/4885
US-20080166364-A1 Conjugated to antibody; thrombospondin receptor targeting TEK, KDR, FLT4 KCNJ1 4881/4885KCNH2 4860/4885MAPT 3372/4885
US-20230012213-A1 NOVEL CONJUGATION CHEMISTRY FOR CATALYTIC ANTIBODY 38C2 PTMS, MRPS34, SDC2 KCNJ1 3655/4885KCNH2 2754/4885MAPT 4075/4885
US-20090098130-A1 GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONIST COMPOUNDS GLP1R, GIPR, GCGR KCNJ1 4243/4885KCNH2 4299/4885MAPT 3456/4885
US-20080152660-A1 Anti-Angiogenic Compounds VEGFA, FLT4, KDR KCNJ1 4873/4885KCNH2 4859/4885MAPT 3908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.